市場調查報告書

全球面部紅斑治療市場:成長,趨勢,及預測

Facial Erythema Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 922025
出版日期 內容資訊 英文 109 Pages
商品交期: 2-3個工作天內
價格
全球面部紅斑治療市場:成長,趨勢,及預測 Facial Erythema Treatment Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年01月01日內容資訊: 英文 109 Pages
簡介

本報告提供全球面部紅斑治療市場的相關調查,提供市場機會和趨勢,成長及阻礙因素,各藥物類型·投藥法·地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 皮膚病患的負擔增加
    • 皮膚病相關研究開發的成長
  • 市場阻礙因素
    • 學名藥的使用增加
    • 嚴格法規
  • 波特的五力分析

第5章 市場區隔

  • 各藥物類型
    • 抗生素
    • 抗真菌劑
    • 抗組織胺藥
    • 皮質類固醇
    • 其他
  • 各投藥法
    • 局部
    • 口服
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Astellas Pharma
    • Bausch Health Companies Inc.
    • GlaxoSmithKline plc
    • LEO Pharma A/S
    • Merck & Co., Inc.
    • Nestle SA (Galderma)
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA

第7章 市場機會及今後趨勢

目錄
Product Code: 67530

Market Overview

The facial erythema treatment market is expected to witness a CAGR of 5%, during the forecast period. Certain factors that are driving the market growth include rising prevalence of rosacea and Growth in Research and Development related to Dermatological Diseases.

Facial erythema can occur due to any skin injury or inflammation and is primarily seen in fair-skinned people. Rosacea and dermatitis are few inflammatory skin disease that causes facial erythema. Rosacea is a common skin disease, which causes redness and visible blood vessels on the face. As per the National Rosacea Society, the United States, the prevalence of rosacea was highest when self-reported, with a rate of 9.71% ( 737,960,000), while the rate of dermatologist-diagnosed rosacea was 5.53% (420,280,000) in 2018. Although there is no cure, treatments can control and reduce the signs and symptoms associated with the disease. With the rising burden of disease and more common occurrence in changing lifestyle, the awareness among the physicians and societies have also increased, which further drives the demand of this market.

Scope of the Report

As per the scope of the report, Facial erythema is basically skin redness, noticeable in fair-skinned individuals, which occurs as a result of cutaneous blood vessel dilation and increased blood flow to the skin. A variety of factors, including primary skin diseases and systemic illness may cause facial redness.

Key Market Trends

Antibiotics Segment is Estimated to Hold the Largest Share of the Market

By drug type, the market has been segmented into Antibiotics, Antifungal, Antihistamines, Corticosteroids, and Others. Antibiotics can reduce the number of acne pimples and bacterial inflammation or redness. It is most commonly preferred by physicians and doctors as compared to other types for early relief from the disease. Topical metronidazole antibiotic is commonly used as a first-line agent. The high demand for antibiotics in the treatment of rosacea is the main factor for the growth of the market. However, there are certain side effects associated with the usage of antibiotics, including bloating, loss of appetite, abdominal pain, and many others, which is expected to restrain their adoption in the forecast period.

North America dominates the Facial Erythema Treatment Market

North America has multiple factors, which support the growth of this market, better than other geographic regions. Some factors include high healthcare expenditure by the government each year on pharmaceuticals and medical devices and awareness in the society. As per the estimates of the National Rosacea Society (NRS), in 2018 about 16 million Americans suffer from rosacea. Such trends are expected to push more patients suffering from symptoms of facial erythema to approach clinics and hospitals, which boosts the studied market in the region. The region is also supported by multiple international companies being collaborated with many major hospital chains, which drives the business of the studied market.

Asia-Pacific is expected to be explored more over the forecast period by the international companies because of the larger target patient pool, changing lifestyle and rapid population growth, better economic growth with higher importance to healthcare facilities and increase in research and development activities.

Competitive Landscape

The major players in the facial erythema treatment market includes Astellas Pharma, Bausch Health Companies Inc., GlaxoSmithKline plc, LEO Pharma A/S, Merck & Co., Inc., Nestle S.A. (Galderma), Merck & Co., Inc., Novartis International AG, and Sanofi, which provides these products across the globe.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Skin Disorders
    • 4.2.2 Growth in Research and Development related to Dermatological Diseases
  • 4.3 Market Restraints
    • 4.3.1 Increased Use of Generic Drugs
    • 4.3.2 Stringent Regulations
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug Type
    • 5.1.1 Antibiotics
    • 5.1.2 Antifungal
    • 5.1.3 Antihistamines
    • 5.1.4 Corticosteroids
    • 5.1.5 Others
  • 5.2 By Mode of Administration
    • 5.2.1 Topical
    • 5.2.2 Oral
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Astellas Pharma
    • 6.1.2 Bausch Health Companies Inc.
    • 6.1.3 GlaxoSmithKline plc
    • 6.1.4 LEO Pharma A/S
    • 6.1.5 Merck & Co., Inc.
    • 6.1.6 Nestle S.A. (Galderma)
    • 6.1.7 Novartis AG
    • 6.1.8 Pfizer Inc.
    • 6.1.9 Sanofi S.A.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS